Pharmaceuticals major Ranbaxy Laboratories plans to make China its major sourcing hub for active pharmaceutical ingredient (API). The company, already has a Chinese presence through a joint venture named Ranbaxy Guangzhou China (RGCL), will explore new partnership options to facilitate raw material outsourcing. RGCL will continue to focus on manufacturing medicines for exclusive supplies to the Chinese market. China’s low-cost raw material manufacturing ability is an opportunity for reducing manufacturing expenses for pharmaceutical companies. Ranbaxy plans to create a lot of value by leveraging on the strength of its newly acquired biotech company, Zenotech Laboratories. Zenotech has two biotechnology-based cancer offerings in India and eight more are being developed. Its medicines are expected to be cleared for shipping to Europe by 2011. Sources say that the company is also expecting to expand its bio-similar drugs (low cost biotechnology medicines) business in a big way, and may also enter speciality areas, such as oncology where there is less competition.